Deals this week: North China Pharmaceutical, Arena Pharmaceuticals, Enterome Bioscience

Chinese pharmaceutical company North China Pharmaceutical has announced the completion of a public offering of ten million short-term bonds to raise CNY1bn ($146.93m).

Priced at CNY100 ($14.69) each, the bonds are due 3 April 2018 and carry a rate of 5.3%.

Arena Pharmaceuticals has announced an underwritten public offering of common stock shares to raise $150m.

The US-based biopharmaceutical company plans to use the funds towards the clinical and pre-clinical development of its drug candidates.

"Arena Pharmaceuticals has announced an underwritten public offering of common stock shares to raise $150m."

Enterome Bioscience and Nestle’s subsidiary Nestle Health Science have announced the formation of a joint venture named Microbiome Diagnostics Partners (MDP).

The JV company will be engaged in the discovery, development and commercialisation of diagnostics in multiple disease areas.

Enterome is a drug development company based in France, while Nestle Health Science is a US-based health science company.